Giuliana Grossi is an editor for The American Journal of Managed Care®, overseeing the publication's Center on Health Equity & Access. Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.
Before Giuliana joined AJMC, she delved into rare disease coverage at HCPLive®, a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in Population Health, Equity & Outcomes® (formerly The American Journal of Accountable Care®), Evidence-Based Oncology®, NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive.
She received her bachelor's degree in creative writing and psychology from Eckerd College and continued her postgraduate studies at the University of Florida's College of Journalism and Communications.
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Physician-Led Tech Firms Use AI to Counter Drug Denials and Augment Appeals
April 16th 2025As drug denials increase, experts discuss the importance of optimizing data to keep up with these changes and implementing artificial intelligence (AI) to reduce the burden on providers and ensure patient access to care and treatment.
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
National Data Show Rising Risk, Cost of CKD in Patients With Acute Myocardial Infarction
April 10th 2025A series of new studies from the National Kidney Foundation Spring Clinical Meeting exhibit the association between impaired kidney function and prolonged hospital stays, higher charges, and greater resource utilization.
Collaborative Care Model Offers Success in Reducing Suicide Risk, New Report Finds
April 10th 2025A report published today by Shatterproof and The Bowman Family Foundation underscores the potential of the collaborative care model to lower suicide risk across diverse patient populations and health systems.
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Meta-Analysis Finds SGLT2 Inhibitors Boost Hemoglobin, Hematocrit in CKD
April 8th 2025The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established benefits but also for addressing anemia.
FINEARTS-HF Data Examine Finerenone Across Bilirubin Levels: Jawad Haider Butt, MD, PhD
April 2nd 2025Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in reducing cardiovascular death did not significantly differ across baseline bilirubin tertiles.